Literature DB >> 16874011

Roles of adenosine receptor subtypes in the antinociceptive effect of intrathecal adenosine in a rat formalin test.

Myung Ha Yoon1, Hong Beom Bae, Jeong Il Choi, Seok Jai Kim, Sung Tae Chung, Chang Mo Kim.   

Abstract

The contributions of adenosine receptor subtypes to antinociception produced by adenosine were determined at the spinal level. There are 4 types of adenosine receptors, namely A1, A(2A), A(2B) and A3. The authors investigated the properties of the subtypes of spinal adenosine receptors in terms of nociceptive modulation. The nociceptive state was induced by subcutaneously injecting formalin solution (5%, 50 microl) into the hind paws of male Sprague-Dawley rats. After observing the effect of intrathecal adenosine during the formalin test, the effects of intrathecal adenosine A1 (CPT), A(2A) (CSC), A(2B) (alloxazine) and A3 (MRS 1220) receptor antagonists on the action of adenosine were examined. Intrathecal adenosine inhibited phase 2 flinching response without affecting phase 1 response. CPT, CSC, alloxazine and MRS 1220 antagonized the antinociceptive action of adenosine during phase 2 of the formalin test. These results suggest that spinal adenosine A1, A(2A), A(2B) and A3 receptors may play an important role in the antinociception of adenosine in the formalin-induced facilitated state. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16874011     DOI: 10.1159/000094762

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

1.  Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists.

Authors:  Zhan-Guo Gao; R Rama Suresh; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2021-10-28       Impact factor: 3.765

Review 2.  Current developments in intraspinal agents for cancer and noncancer pain.

Authors:  Erin F Lawson; Mark S Wallace
Journal:  Curr Pain Headache Rep       Date:  2010-02

Review 3.  Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.

Authors:  K Janes; A M Symons-Liguori; K A Jacobson; D Salvemini
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

Review 4.  Adenosine receptors: Emerging non-opioids targets for pain medications.

Authors:  Soo-Min Jung; Lee Peyton; Hesham Essa; Doo-Sup Choi
Journal:  Neurobiol Pain       Date:  2022-03-25

5.  Treatment of chronic neuropathic pain: purine receptor modulation.

Authors:  Kenneth A Jacobson; Luigino Antonio Giancotti; Filomena Lauro; Fatma Mufti; Daniela Salvemini
Journal:  Pain       Date:  2020-07       Impact factor: 7.926

Review 6.  Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain.

Authors:  Fabrizio Vincenzi; Silvia Pasquini; Pier Andrea Borea; Katia Varani
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.